From the lab to everyday life
“We saw the challenges and failures faced by researchers and healthcare providers, and we knew we could help. We want to facilitate the ability to show what is occuring at a molecular level, to predict changes before they happen and to treat causes, not just symptoms “
We believe that improved data will help us diagnose and develop cures quicker, all at a lower cost.
Our mission is to continuously iterate the technology and to create a globally used data platform to make this a reality.
Our research tools are already transforming scientists’ understanding of the biological world. Our vision of this technology powering tools in the clinical setting is close to realisation. Rapid and early diagnosis, predictive and proactive healthcare improving patient outcomes is all within sight.
Alzheimer’s drug discovery
Eli Lilly spent $3bn on three Alzheimer’s Disease drugs, yet solanezumab failed to work.
JNJ spent $1bn for partial rights to bapineuzumab, it failed.
Roche spent a similar sum on gantenerumab before it failed.
This is because nobody understood the mechanism of action of any of these drugs, until Professor Sara Linse’s work with the Fluidity One-W (presented July 2019 at FEBS).
In the future, companies could understand the mechanism of action of their drugs throughout development, saving time, effort and cost and ultimately, producing a drug that works.
Organ transplant surgery
The lack of clinical ability to predict rejection leads to overuse of immunosuppressant drugs.
Spend on immunosuppressant drugs exceeds $3bn p/a worldwide.
Current diagnostic tests to predict and monitor rejection responses have low clinical relevance.
Alternative approaches had failed to produce a clinically relevant, serum-based assay.
Transplant surgeon Vasilis Kosmoliaptsis is using our technology in the Fluidity One-W to resolve this issue.
Fluidic enables doctors to accurately predict organ rejection probability and optimise dosing of immunosuppressant drugs.
Reduced costs, reduced suffering, improved patient outcomes.
Our equipment is accessible and easy to use, we aim to put this technology in the hands of everyone who could benefit, fundamentally improving lives.
Our culture of openness and integrity permeates everything we do. Accessibility and usability of our products, continuous exchange of ideas with collaborators and our commitment to our users’ complete ownership of their data. Our mission is to see tailored, effective therapies to benefit mankind.
We are continuously developing to incorporate more scientific areas, and therefore more diseases like cancer, Alzheimer’s, diabetes and asthma and more conditions like allergies and eczema.
Our first clinical applications are being established at the proof of principle stage by our clinical collaborators. We are now ISO-13485 certified, meaning we can now propel Fluidic Analytics' technology into companion diagnostics, precision medicine and consumer health.
Simultaneously, our clinical collaborators are already establishing our first clinical applications at the proof of principle stage. With ISO-13485 certification, this proof of principle will allow us to further help companion diagnostics, precision medicine and consumer health.
We envisage a Protein Registry as a resource to benefit humanity. This database will facilitate the cutting-edge research of protein behaviours in normal health and in disease and encourage global collaboration.
Individuals will be able to continuously update their protein profile which will be anonymised, enabling researchers to analyse patterns in health and disease. Healthcare providers will be able to accurately diagnose and predict and potentially prevent disease at the first molecular changes.
Drug development can be refined, efficient and effective based on comprehensive and revolutionary protein data.